hotspot -WSS

hotspot

author：hotspot 2025-10-01 21:48:03 - browse：6537

Jeremey Wyatt ActiGraph

As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

The Pensacola, Fla.-based company creates devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Will Ozempic

WSS

The explosion of genetic testing requires a new approach

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

FDA gives detailed accounting of AI

First Opinion Podcast: Long Covid needs a new approach

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

FDA gives detailed accounting of AI

Wikipedia

hotspot

focus

Dobbs anniversary: the lost opportunity of abortion as health care

NIH confirmation hearing shows politicization of research

Walensky prepares to leave CDC — and Congress — behind

2 US Navy sailors arrested for allegedly spying for China

Medical records are filled with copy

ER docs worry over extreme heat as a 'mass casualty event'

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dramatically reducing cancer deaths requires the PASTEUR Act

Duchenne breakthrough therapy leaves behind pioneering families

TytoCare raises $49 million to build out AI

leisure time

Impact of Dobbs ruling felt at reproductive medicine meeting

Dramatically reducing cancer deaths requires the PASTEUR Act

First Opinion Podcast: Long Covid needs a new approach

Stem cell clinics for heart failure: buyer be wary

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Senate committee scrutinizes Medicare Advantage brokers

entertainment

hotspot

entertainment

hotspot